• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Compliance with Cyproterone Contraindications and Meningioma Risk: Resource-Efficient Use of Aggregated Statistics from Swedish National Health Registers.

作者信息

Kälkner Karl Mikael, Sundström Anders, Ljung Rickard

机构信息

Pharmacoepidemiology and Analysis Department, Swedish Medical Product Agency, P.O. Box 26, 751 03, Uppsala, Sweden.

Department of Pharmacy, Uppsala University, Uppsala, Sweden.

出版信息

Pharmaceut Med. 2025 Mar;39(2):143-145. doi: 10.1007/s40290-025-00560-3. Epub 2025 Mar 15.

DOI:10.1007/s40290-025-00560-3
PMID:40087203
Abstract
摘要

相似文献

1
Compliance with Cyproterone Contraindications and Meningioma Risk: Resource-Efficient Use of Aggregated Statistics from Swedish National Health Registers.醋酸环丙孕酮禁忌证的依从性与脑膜瘤风险：瑞典国家卫生登记处汇总统计数据的高效利用
Pharmaceut Med. 2025 Mar;39(2):143-145. doi: 10.1007/s40290-025-00560-3. Epub 2025 Mar 15.
2
Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study.大剂量醋酸环丙孕酮的使用与女性颅内脑膜瘤风险：队列研究。
BMJ. 2021 Feb 3;372:n37. doi: 10.1136/bmj.n37.
3
Abrupt regression of a meningioma after discontinuation of cyproterone treatment.环丙孕酮治疗中断后脑膜瘤突然消退。
AJNR Am J Neuroradiol. 2010 Sep;31(8):1504-5. doi: 10.3174/ajnr.A1978. Epub 2010 Jan 6.
4
Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study.与普通人群相比，大剂量环丙孕酮使用者罹患脑膜瘤的风险：一项基于人群的队列研究证据。
Br J Clin Pharmacol. 2011 Dec;72(6):965-8. doi: 10.1111/j.1365-2125.2011.04031.x.
5
[Intra cranial meningiomas and long term use of cyproterone acetate with a conventional dose in women. A report of two cases of tumor decrease after treatment withdrawal].[颅内脑膜瘤与女性长期常规剂量使用醋酸环丙孕酮。两例停药后肿瘤缩小的病例报告]
Neurochirurgie. 2015 Oct;61(5):339-42. doi: 10.1016/j.neuchi.2015.05.002. Epub 2015 Aug 4.
6
High-Dose Cyproterone Acetate and Intracranial Meningioma: Impact of the Risk Minimisation Measures Implemented in France in 2018-2019.大剂量醋酸环丙孕酮与颅内脑膜瘤：法国2018 - 2019年实施的风险最小化措施的影响
Pharmacoepidemiol Drug Saf. 2025 Jan;34(1):e70078. doi: 10.1002/pds.70078.
7
Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report.醋酸环丙孕酮和醋酸诺美孕酮对脑膜瘤的联合激素影响：一例报告
Acta Neurochir (Wien). 2019 Mar;161(3):589-592. doi: 10.1007/s00701-018-03782-4. Epub 2019 Jan 22.
8
Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma.脑膜瘤与醋酸环丙孕酮：一项对388例接受手术或放疗治疗颅内脑膜瘤患者的回顾性单中心队列研究。
J Neurooncol. 2021 Mar;152(1):115-123. doi: 10.1007/s11060-020-03683-6. Epub 2021 Jan 3.
9
Cyproterone acetate and meningioma: a nationwide-wide population based study.醋酸环丙孕酮与脑膜瘤：一项全国范围内基于人群的研究。
J Neurooncol. 2021 Jan;151(2):331-338. doi: 10.1007/s11060-020-03672-9. Epub 2021 Jan 4.
10
[Should cyproterone acetate be removed from our prescriptions?].醋酸环丙孕酮是否应从我们的处方中去除？
Gynecol Obstet Fertil Senol. 2019 Dec;47(12):823-824. doi: 10.1016/j.gofs.2019.10.006. Epub 2019 Oct 18.

本文引用的文献

1
High-Dose Cyproterone Acetate and Intracranial Meningioma: Impact of the Risk Minimisation Measures Implemented in France in 2018-2019.大剂量醋酸环丙孕酮与颅内脑膜瘤：法国2018 - 2019年实施的风险最小化措施的影响
Pharmacoepidemiol Drug Saf. 2025 Jan;34(1):e70078. doi: 10.1002/pds.70078.
2
Use of Reporting Recommendation Intended for Pharmaceutical Risk Minimisation Evaluation Studies (RIMES) Checklist in Risk Minimisation/Mitigation Studies: A Review and Survey.用于最小化药品风险评估研究（RIMES）清单在风险最小化/缓解研究中的应用：综述与调查
Drug Saf. 2025 Apr;48(4):415-423. doi: 10.1007/s40264-024-01504-7. Epub 2024 Dec 17.
3
Physician Awareness of the Safe Use of Cyproterone Acetate in Europe: A Survey on the Effectiveness of Additional Risk Minimization Measures.
欧洲医生对醋酸环丙孕酮安全使用的认知：额外降低风险措施效果的调查。
Pharmaceut Med. 2024 Mar;38(2):145-156. doi: 10.1007/s40290-023-00510-x. Epub 2024 Jan 31.
4
Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021.2016 年至 2021 年间，欧洲药品管理局评估的降低风险措施有效性研究综述。
Clin Pharmacol Ther. 2023 Dec;114(6):1285-1292. doi: 10.1002/cpt.3034. Epub 2023 Oct 16.
5
Are risk minimization measures for approved drugs in Europe effective? A systematic review.在欧洲，已批准药物的风险最小化措施是否有效？一项系统评价。
Expert Opin Drug Saf. 2019 May;18(5):443-454. doi: 10.1080/14740338.2019.1612875. Epub 2019 May 20.